15 research outputs found
Supplementary Material for: Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease
<p><b><i>Background/Aims:</i></b> To evaluate whether visual assessment
of medial temporal lobe atrophy (vaMTA) can predict 2-year conversion
from mild cognitive impairment (MCI) to dementia and progression of MCI
and Alzheimer's disease dementia as measured by the Clinical Dementia
Rating Scale Sum of Boxes score (CDR-SB). <b><i>Methods:</i></b> vaMTA
was performed in 94 patients with MCI according to the Winblad criteria
and in 124 patients with AD according to ICD-10 and NINCDS-ADRDA
criteria. Demographic data, the Consortium to Establish a Registry for
Alzheimer's Disease 10-word delayed recall, APOE ɛ4 status, Cornell
Scale for Depression in Dementia, and comorbid hypertension were used as
covariates. <b><i>Results:</i></b> vaMTA was associated with MCI conversion in an unadjusted model but not in an adjusted model (<i>p</i>
= 0.075), where delayed recall and APOE ɛ4 status were significant
predictors. With CDR-SB change as the outcome, an interaction between
vaMTA and diagnosis was found, but in the adjusted model only delayed
recall and age were significant predictors. For vaMTA below 2, the
association between vaMTA and CDR-SB change differed between diagnostic
groups. Similar results were found based on a trajectory analysis. <b><i>Conclusion:</i></b>
In adjusted models, memory function, APOE ɛ4 status and age were
significant predictors of disease progression, not vaMTA. The
association between vaMTA and CDR-SB change was different in patients
with MCI and Alzheimer's disease dementia.</p
Corrigendum: Whole-genome sequencing identifies rare genotypes in COMP and CHADL associated with high risk of hip osteoarthritis.
To access publisher's full text version of this article click on the hyperlink belo